Charles E. Myers
#126,540
Most Influential Person Now
Charles E. Myers's AcademicInfluence.com Rankings
Charles E. Myersbiology Degrees
Biology
#8050
World Rank
#11064
Historical Rank
Neuroscience
#1094
World Rank
#1136
Historical Rank
Biochemistry
#1148
World Rank
#1266
Historical Rank
Download Badge
Chemistry Biology
Charles E. Myers's Degrees
- PhD Biochemistry Stanford University
- Bachelors Chemistry University of California, Berkeley
Why Is Charles E. Myers Influential?
(Suggest an Edit or Addition)Charles E. Myers's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation. (1994) (1459)
- Adriamycin: the role of lipid peroxidation in cardiac toxicity and tumor response. (1977) (1139)
- Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. (1999) (1024)
- Overexpression of a novel anionic glutathione transferase in multidrug-resistant human breast cancer cells. (1986) (762)
- The anthracycline antineoplastic drugs. (1981) (760)
- ADMINISTRATION OF 3'-AZIDO-3'-DEOXYTHYMIDINE, AN INHIBITOR OF HTLV-III/LAV REPLICATION, TO PATIENTS WITH AIDS OR AIDS-RELATED COMPLEX (1986) (733)
- Enzymatic defenses of the mouse heart against reactive oxygen metabolites: alterations produced by doxorubicin. (1980) (722)
- Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. (1978) (712)
- Inhibition of arachidonate 5-lipoxygenase triggers massive apoptosis in human prostate cancer cells. (1998) (491)
- PHASE I STUDIES OF 2',3'-DIDEOXYCYTIDINE IN SEVERE HUMAN IMMUNODEFICIENCY VIRUS INFECTION AS A SINGLE AGENT AND ALTERNATING WITH ZIDOVUDINE (AZT) (1988) (464)
- Establishment and characterization of a human adrenocortical carcinoma cell line that expresses multiple pathways of steroid biosynthesis. (1990) (427)
- Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer. (1996) (397)
- Plasma and cerebrospinal fluid pharmacokinetics of 3′‐azido‐3′‐deoxythymidine: A Novel pyrimidine analog with potential application for the treatment of patients with AIDS and related diseases (1987) (375)
- Suramin: an anticancer drug with a unique mechanism of action. (1989) (367)
- Expression of anionic glutathione-S-transferase and P-glycoprotein genes in human tissues and tumors. (1989) (365)
- Clinical pharmacology of 3'-azido-2',3'-dideoxythymidine (zidovudine) and related dideoxynucleosides. (1989) (329)
- RESPONSE OF HUMAN-IMMUNODEFICIENCY-VIRUS-ASSOCIATED NEUROLOGICAL DISEASE TO 3'-AZIDO-3'-DEOXYTHYMIDINE (1987) (321)
- Similar biochemical changes associated with multidrug resistance in human breast cancer cells and carcinogen-induced resistance to xenobiotics in rats. (1986) (290)
- Plasma pharmacokinetics of adriamycin and adriamycinol: implications for the design of in vitro experiments and treatment protocols. (1983) (281)
- Arachidonic acid stimulates prostate cancer cell growth: critical role of 5-lipoxygenase. (1997) (275)
- Adriamycin-induced free radical formation in the perfused rat heart: implications for cardiotoxicity. (1988) (264)
- Pharmacokinetics of adriamycin and tissue penetration in murine ovarian cancer. (1979) (264)
- Phase I and pharmacological studies of 5-fluorouracil administered intraperitoneally. (1980) (256)
- Terminal neuroendocrine differentiation of human prostate carcinoma cells in response to increased intracellular cyclic AMP. (1994) (254)
- Rho-kinase inhibitor retards migration and in vivo dissemination of human prostate cancer cells. (2000) (245)
- Prevention of doxorubicin cardiac toxicity in the mouse by N-acetylcysteine. (1981) (240)
- Phase I and Pharmacological Studies of Adriamycin Administered Intraperitoneally to Patients with Ovarian Cancer (1982) (233)
- Differential formation of hydroxyl radicals by adriamycin in sensitive and resistant MCF-7 human breast tumor cells: implications for the mechanism of action. (1987) (222)
- High-dose cisplatin in hypertonic saline in refractory ovarian cancer. (1985) (218)
- Portal levels and hepatic clearance of 5-fluorouracil after intraperitoneal administration in humans. (1981) (207)
- The pharmacology of the fluoropyrimidines. (1981) (201)
- The Clinical Pharmacology of Antineoplastic Agents (1975) (199)
- Carcinogen-induced mdr overexpression is associated with xenobiotic resistance in rat preneoplastic liver nodules and hepatocellular carcinomas. (1987) (196)
- Nonlinear pharmacokinetic models for 5‐fluorouracil in man: Intravenous and intraperitoneal routes (1980) (190)
- EFFECTS OF SURAMIN ON HTLV-III/LAV INFECTION PRESENTING AS KAPOSI'S SARCOMA OR AIDS-RELATED COMPLEX: CLINICAL PHARMACOLOGY AND SUPPRESSION OF VIRUS REPLICATION IN VIVO (1985) (188)
- Doxorubicin cardiotoxicity: assessment of late left ventricular dysfunction by radionuclide cineangiography. (1981) (162)
- Adriamycin activation and oxygen free radical formation in human breast tumor cells: protective role of glutathione peroxidase in adriamycin resistance. (1989) (161)
- Hydroxyl radical production and DNA damage induced by anthracycline‐iron complex (1984) (146)
- Clinical Pharmacokinetics of Suramin in Patients With HTLV‐III/LAV Infection (1986) (144)
- A Phase II Study of 5-AZA-2'Deoxycytidine (Decitabine) in Hormone Independent Metastatic (D2) Prostate Cancer (1998) (141)
- Selective growth arrest and phenotypic reversion of prostate cancer cells in vitro by nontoxic pharmacological concentrations of phenylacetate. (1993) (139)
- A Phase I and Pharmacokinetic Study of Diamminecyclobutanedicarboxylatoplatinum (NSC 241240) (1983) (137)
- Surprising activity of flutamide withdrawal, when combined with aminoglutethimide, in treatment of "hormone-refractory" prostate cancer. (1994) (137)
- Biochemical determinants of 5-fluorouracil response in vivo. The role of deoxyuridylate pool expansion. (1975) (133)
- Long-term results of a cisplatin-containing combination chemotherapy regimen for the treatment of advanced ovarian carcinoma. (1986) (132)
- Phase I study of phenylacetate administered twice daily to patients with cancer (1995) (132)
- Potentiation of doxorubicin cytotoxicity by buthionine sulfoximine in multidrug-resistant human breast tumor cells. (1989) (132)
- Glucose metabolism in drug-sensitive and drug-resistant human breast cancer cells monitored by magnetic resonance spectroscopy. (1988) (128)
- Drug-induced apoptosis is not necessarily dependent on macromolecular synthesis or proliferation in the p53-negative human prostate cancer cell line PC-3. (1995) (125)
- Increased radioresistance of ejras‐transformed human osteosarcoma cells and its modulation by lovastatin, an inhibitor of p21ras isoprenylation (1993) (125)
- Mode of action of 5-fluorocytosine. (1978) (124)
- Isolation of the human anionic glutathione S-transferase cDNA and the relation of its gene expression to estrogen-receptor content in primary breast cancer. (1988) (123)
- Suramin‐induced polyneuropathy (1990) (118)
- The clinical pharmacology of antineoplastic agents (second of two parts). (1975) (117)
- Selective activity of phenylacetate against malignant gliomas: resemblance to fetal brain damage in phenylketonuria. (1994) (115)
- Pharmacological evaluation of intravenous delivery of 5-bromodeoxyuridine to patients with brain tumors. (1984) (115)
- High-volume intraperitoneal chemotherapy with methotrexate in patients with cancer. (1981) (112)
- Adriamycin: amelioration of toxicity by alpha-tocopherol. (1976) (111)
- Alteration of zidovudine pharmacokinetics by probenecid in patients with AIDS or AIDS‐related complex (1989) (110)
- Evaluation of tamoxifen dose in advanced breast cancer: a progress report. (1976) (110)
- Adriamycin-stimulated hydroxyl radical formation in human breast tumor cells. (1987) (107)
- Intraperitoneal contrast infusion for assessment of intraperitoneal fluid dynamics. (1979) (107)
- Differential oxygen radical susceptibility of adriamycin-sensitive and -resistant MCF-7 human breast tumor cells. (1989) (103)
- Adriamycin accumulation and metabolism in adriamycin-sensitive and -resistant human ovarian cancer cell lines. (1986) (103)
- Pharmacokinetics of 2‘,3’‐Dideoxycytidine in Patients with AIDS and Related Disorders (1988) (99)
- A Phase I study of intermittent intravenous bromodeoxyuridine (BUdR) with conventional fractionated irradiation. (1984) (97)
- A Phase II study of high-dose tamoxifen in patients with hormone-refractory prostate cancer. (1999) (97)
- Subcutaneous recombinant granulocyte-macrophage colony-stimulating factor used as a single agent and in an alternating regimen with azidothymidine in leukopenic patients with severe human immunodeficiency virus infection. (1990) (95)
- Pharmacokinetics of the fluoropyrimidines: implications for their clinical use. (1976) (94)
- Inhibition of human ovarian cancer colony formation by adriamycin and its major metabolites. (1980) (93)
- Prospective evaluation of doxorubicin cardiotoxicity by rest and exercise radionuclide angiography. (1986) (93)
- P2-purinergic receptor agonists inhibit the growth of androgen-independent prostate carcinoma cells. (1992) (92)
- The effect of doxorubicin on hepatic and cardiac glutathione. (1979) (88)
- Long‐term administration of 3′‐Azido‐2′,3′‐dideoxythymidine to patients with AIDS‐related neurological disease (1988) (86)
- Suramin in adrenal cancer: modulation of steroid hormone production, cytotoxicity in vitro, and clinical antitumor effect. (1990) (86)
- Prostate specific antigen decline following the discontinuation of flutamide in patients with stage D2 prostate cancer. (1995) (86)
- Pharmacology of intraperitoneal chemotherapy. (1983) (85)
- Pharmacology of 13-cis-retinoic acid in humans. (1982) (79)
- Effect of suramin on human prostate cancer cells in vitro. (1991) (79)
- Suramin inhibits bFGF-induced endothelial cell proliferation and angiogenesis in the chick chorioallantoic membrane. (1993) (78)
- Clinical pharmacology of anticancer drugs. (1977) (77)
- Prospective randomized trial of intravenous v intraperitoneal 5-FU in patients with advanced primary colon or rectal cancer. (1985) (76)
- Antitumor activity of suramin in hormone‐refractory prostate cancer controlling for hydrocortisone treatment and flutamide withdrawal as potentially confounding variables (1995) (73)
- Selenium-induced cytotoxicity of human leukemia cells: interaction with reduced glutathione. (1986) (71)
- Prospective randomized study of the role of N‐acetyl cysteine in reversing doxorubicin‐induced cardiomyopathy (1982) (68)
- Cyclic AMP induces transforming growth factor beta 2 gene expression and growth arrest in the human androgen-independent prostate carcinoma cell line PC-3. (1992) (66)
- Activin inhibition of prostate cancer cell growth: selective actions on androgen-responsive LNCaP cells. (1996) (65)
- Disposition of Phenylbutyrate and its Metabolites, Phenylacetate and Phenylacetylglutamine (1995) (65)
- Bone marrow involvement in Hodgkin's disease: pathology and response to MOPP chemotherapy. (1974) (64)
- Technical considerations in the use of intraperitoneal chemotherapy administered by Tenckhoff catheter. (1982) (64)
- Competitive protein binding assay of methotrexate. (1975) (63)
- Assay of 5-fluorodeoxyuridine 5'-monophosphate deoxyuridine 5'-monophosphate pools following 5-fluorouracil. (1974) (63)
- Glutathione S-transferase and drug resistance. (1989) (62)
- Phenylacetate and phenylbutyrate as novel, nontoxic differentiation inducers. (1997) (62)
- Paclitaxel (taxol) inhibits protein isoprenylation and induces apoptosis in PC-3 human prostate cancer cells. (1995) (61)
- Monoclonal antibodies to glutathione S‐Transferase π–immunohistochemical analysis of human tissues and cancers (1991) (56)
- Experimental animal models of adriamycin cardiotoxicity. (1979) (56)
- Regulation of the cytidine phospholipid pathways in human cancer cells and effects of 1-beta-D-arabinofuranosylcytosine: a noninvasive 31P nuclear magnetic resonance study. (1990) (54)
- Use of suramin in treatment of prostatic carcinoma refractory to conventional hormonal manipulation. (1991) (54)
- Suramin, a novel antitumor compound (1990) (53)
- Prognostic factors for survival of patients with bidimensionally measurable metastatic hormone‐refractory prostatic cancer treated with single‐agent chemotherapy (1992) (53)
- Kinetic characterization and response to chemotherapy in a transplantable murine ovarian cancer. (1979) (52)
- Adriamycin resistance in human tumor cells associated with marked alteration in the regulation of the hexose monophosphate shunt and its response to oxidant stress. (1987) (52)
- Role of iron in adriamycin biochemistry. (1986) (51)
- Suramin: prototype of a new generation of antitumor compounds. (1990) (51)
- Synergistic activity of suramin with tumor necrosis factor alpha and doxorubicin on human prostate cancer cell lines. (1990) (51)
- A pilot study of suramin in the treatment of metastatic renal cell carcinoma (1991) (50)
- The detergent Triton X‐100 induces a death pattern in human carcinoma cell lines that resembles cytotoxic lymphocyte‐induced apoptosis (1994) (50)
- Circulating glycosaminoglycan anticoagulants associated with suramin treatment. (1988) (50)
- Specific labeling of isoprenylated proteins: application to study inhibitors of the post-translational farnesylation and geranylgeranylation. (1995) (49)
- Altered regulation of P-450IA1 expression in a multidrug-resistant MCF-7 human breast cancer cell line. (1988) (49)
- Lipoxygenase Inhibition in Prostate Cancer (1999) (48)
- New developments on the mechanisms of action of antineoplastic drugs. (1979) (48)
- Growth inhibition, tumor maturation, and extended survival in experimental brain tumors in rats treated with phenylacetate. (1994) (47)
- The use of peritoneal dialysis for delivery of chemotherapy to intraperitoneal malignancies. (1980) (47)
- Phenylacetate inhibits protein isoprenylation and growth of the androgen-independent LNCaP prostate cancer cells transfected with the T24 Ha-ras oncogene. (1996) (46)
- Enhancement of paclitaxel activity against hormone-refractory prostate cancer cells in vitro and in vivo by quinacrine. (1997) (43)
- Ocular irritation from high‐dose methotrexate therapy: Pharmacokinetics of drug in the tear film (1981) (43)
- Cytostatic activity of phenylacetate and derivatives against tumor cells. Correlation with lipophilicity and inhibition of protein prenylation. (1995) (42)
- A phase I/II study of continuous infusion suramin in patients with hormone-refractory prostate cancer : toxicity and response (1996) (41)
- Use of the aromatase inhibitor anastrozole in the treatment of patients with advanced prostate carcinoma (2001) (41)
- Adaptive control with feedback strategies for suramin dosing (1992) (41)
- Pharmacologic variables associated with the development of neurologic toxicity in patients treated with suramin. (1995) (39)
- Central role of arachidonate 5-lipoxygenase in the regulation of cell growth and apoptosis in human prostate cancer cells. (1999) (39)
- Irreversible binding of etoposide (VP-16-213) to deoxyribonucleic acid and proteins. (1984) (39)
- Analysis of cytidine deaminase and tetrahydrouridine interaction by use of ligand techniques. (1978) (38)
- Serial determinations of glutathione levels and glutathione-related enzyme activities in human tumor cells in vitro. (1986) (38)
- 5-Iminodaunomycin. An anthracycline with unique properties. (1987) (38)
- Chemotherapy for murine ovarian cancer: a rationale for ip therapy with adriamycin. (1979) (35)
- Competitive protein binding assay for methotrexate. (1975) (34)
- Myeloperoxidase: an enzyme involved in intrinsic vincristine resistance in human myeloblastic leukemia. (1993) (34)
- A phase I and pharmacokinetic study of diamminecyclobutane-dicarboxylatoplatinum (NSC 241240). (1983) (34)
- Suramin interference with transforming growth factor-beta inhibition of human renal cell carcinoma in culture. (1992) (34)
- Arachidonic acid metabolism and cancer of the prostate. (1998) (33)
- Metalloporphyrin contrast agents for magnetic resonance imaging of human tumors in mice. (1986) (33)
- Phase II trial of suramin, leuprolide, and flutamide in previously untreated metastatic prostate cancer. (1997) (31)
- Kinetic alterations induced by 5-fluorouracil in bone marrow, intestinal mucosa, and tumor. (1976) (30)
- Reversibility of high-affinity binding of methotrexate in L1210 murine leukemia cells. (1978) (29)
- Role of Iron in Anthracycline Action (1988) (29)
- Suramin-induced skin reactions. (1992) (28)
- Free radical formation by ansamycin benzoquinone in human breast tumor cells: implications for cytotoxicity and resistance. (1994) (27)
- The effect of suramin, tumor necrosis factor and interferon γ on human prostate carcinoma (1991) (25)
- Membrane-bound glutathione peroxidase-like activity in mitochondria. (1980) (24)
- Oncogene overexpression and de novo drug-resistance in human prostate cancer cells. (1994) (24)
- 9-Aminocamptothecin: a topoisomerase I inhibitor with preclinical activity in prostate cancer. (1997) (23)
- EFFECT OF TOCOPHEROL AND SELENIUM ON DEFENSES AGAINST REACTIVE OXYGEN SPECIES AND THEIR EFFECT ON RADIATION SENSITIVITY (1982) (23)
- A pilot study of suramin in the treatment of progressive refractory follicular lymphomas. (1992) (23)
- Cardiac and red blood cell glutathione peroxidase: results of a prospective randomized trial in patients on total parenteral nutrition. (1985) (23)
- MK591, a leukotriene biosynthesis inhibitor, induces apoptosis in prostate cancer cells: synergistic action with LY294002, an inhibitor of phosphatidylinositol 3'-kinase. (2010) (21)
- Suramin rapidly alters cellular tyrosine phosphorylation in prostate cancer cell lines. (1992) (21)
- Suramin inhibits DNA damage in human prostate cancer cells treated with topoisomerase inhibitors in vitro (1993) (21)
- Suramin in advanced platinum-resistant ovarian cancer. (1992) (21)
- Phase II trial of 5-FU administered Ip to patients with refractory ovarian cancer. (1984) (20)
- Enzymatic defense against radiation damage in mice. Effect of selenium and vitamin E depletion. (1986) (18)
- Resistance of paraquat and adriamycin in human breast tumor cells: role of free radical formation. (1989) (18)
- Clinical and experimental evidence of inhibition of testosterone production by suramin. (1996) (16)
- The Role of Free Radical Damage in the Genesis of Doxorubicin Cardiac Toxicity (1982) (15)
- Suramin inhibits bone resorption and reduces osteoblast number in a neonatal mouse calvarial bone resorption assay. (1992) (15)
- Pharmacokinetics of the hypoxic radiosensitizers misonidazole and demethylmisonidazole after intraperitoneal administration in humans. (1983) (15)
- In vitro antitumor effect of hydroxyurea on hormone-refractory prostate cancer cells and its potentiation by phenylbutyrate. (1994) (13)
- 5-HETE congeners as modulators of cell proliferation. (2000) (13)
- Potential strategies for circumventing myeloperoxidase-catalyzed degradation of vinca alkaloids. (1994) (13)
- The clinical pharmacology of antineoplastic agents (first of two parts). (1975) (12)
- Differentiating agents and nontoxic therapies. (1999) (11)
- Antineoplastic Drugs: Clinical Pharmacology and Therapeutic Use (1978) (10)
- Anthracosilicosis and bronchogenic carcinoma. (1967) (10)
- Competitive binding radioassay for 5-fluorodeoxyuridine 5'-monophosphate in tissues. (1979) (10)
- Molecular mechanisms of prostate cancer cell death triggered by inhibition of arachidonate 5-lipoxygenase: involvement of Fas death receptor-mediated signals. (2002) (10)
- Vincristine degradation by serum from leukemic patients: role of myeloperoxidase. (1996) (8)
- Potential clinical applications of a new method for quantitation of plasma levels of 5-fluorouracil and 5-fluorodeoxyuridine. (1979) (8)
- Chemotherapy in advanced disease (1982) (8)
- Phase II study of high-dose methotrexate in patients with advanced malignant melanoma. (1979) (8)
- A Simultaneous Assay of the Differentiating Agents, Phenylacetic Acid and Phenylbutyric Acid, and One of Their Metabolites, Phenylacetyl-Glutamine, by Reversed-Phase, High Performance Liquid Chromatography (1994) (7)
- Suramin decreases circulating levels of insulin-like growth factor-I. (1994) (7)
- Anaphylactoid Reaction With Suramin (1993) (7)
- Metastatic Cancer of Cowper's Gland: A Rare Cancer Managed Successfully by Molecular Profiling (2014) (6)
- Glutathione peroxidase. Its role in adriamycin cardiotoxicity. Abstr. (1977) (6)
- Principles and practice of intraperitoneal therapy. (1988) (5)
- Workshop on suramin with emphasis on prostate cancer: re-evaluation of response criteria. (1993) (5)
- The role of doxorubicin-iron complex in superoxide production and membrane damage (1981) (5)
- Biliary colic heralding systemic relapse in non‐hodgkin lymphoma (1980) (4)
- Suramin administration is associated with a decrease in serum calcium levels (2000) (4)
- Frequency of BRCA mutations and co-occurring alterations in prostate cancer. (2016) (4)
- Evaluation of weekly escalating doses of dichloromethotrexate in patients with hepatocellular carcinoma and other solid tumors (2004) (4)
- [30] Competitive protein binding assay of methotrexate (1982) (3)
- Suramin therapy for malignant thymoma: a case report. (1994) (3)
- Ovarian cancer (oc): intraperitoneal (i.p.) Therapy with adriamycin (adr). Abstr. (1979) (3)
- Competitive protein binding assay for methotrexate ( dihydrofolate reductase / drug-enzyme affinity / methotrexate pharmacokinetics ) (2)
- Preventing drug diversions. (1994) (2)
- Pharmacology of bromodeoxyuridine (NSC 38297) given by peripheral venous infusion (1982) (2)
- A Phase II Study of High-Dose Tamoxifen in Patients with Hormone-refractory Prostate Cancer 1 (1999) (2)
- ANTHRACOSILICO-TUBERCULOSIS AS SEEN IN A GENERAL HOSPITAL. (1963) (2)
- Meeting summary: Workshop conference on endocrine therapy of advanced prostate cancer, airlie house, November 3-4, 1996. (1997) (2)
- The prevention of doxorubicin cardiac toxicity by n-acetyl- l-cysteine. Abstr. (1979) (2)
- Clinical pharmacology of 13-cis retinoic acid (1981) (2)
- Effects of tocopherol on adriamycin-induced cardiomyopathy and tumor response. Abstr. (1977) (1)
- The effect of suramin, tumor necrosis factor and interferon gamma on human prostate carcinoma. (1991) (1)
- Metabolic changes associated with drug resistance in human breast cancer cells monitored by magnetic resonance spectroscopy mrs (1987) (1)
- The Role of Selenium Compounds in Cancer Therapy (1986) (1)
- Eligibility a nd R esponse G uidelines f or P hase I I C linical Trials i n A ndrogen-Indepen dent P rostate C ancer: Recommendations F rom t he P rostate-Specifi c A ntigen Working G roup (1999) (1)
- Molecular profiling of advanced refractory prostate cancer. (2014) (1)
- Current concepts in cancer: ovary--treatment for stages III and IV. Chemotherapy in advanced disease. (1982) (1)
- Kinetic alterations induced by 5-fu in vivo, the simultaneous effect of chemotherapy on bone marrow, intestinal mucosa and ehrlich's ascites tumor. Abstr. (1973) (1)
- Intraperitoneal Adriamycin in Ovarian Cancer (1982) (1)
- Establishment and Characterization of a Human Adrenocortical Carcinoma Cell Line That Expresses Multiple Pathways of Steroid Biosynthesis1 (2006) (1)
- Intraperitoneal chemotherapy. (1984) (1)
- Cytotoxic drugs active in leukemia (1984) (1)
- Letters to the editor (1)
- Bone Marrow Involvement in Hodgkin's Disease (HD): Pathology and Clinical Implications. (1973) (1)
- The use of intraperitoneal chemotherapy. (1985) (1)
- Pharmacology of 13-c/s-Retinoic Acid in Humans1 (1982) (1)
- The clinical setting and pharmacology of intraperitoneal chemotherapy: an overview. (1985) (1)
- Preclinical evaluation of aclacinomycin A for the intraperitoneal treatment of human ovarian carcinoma (2004) (1)
- Use of paramagnetic metalloporphyrins as contrast agents for tumors in MRI imaging (1992) (1)
- Competitive dihydrofolate reductase binding assay of triazinate (NSC-139105), methasquin (NSC-122870), and aminopterin (NSC739). (1976) (0)
- Preparing a list of cytotoxic agents (1987) (0)
- Neuroendocrine Differentiation and Epithelial to Mesenchymal Transition in Prostate Cancer: cAMP-Dependent Signaling as a Therapeutic Target (2015) (0)
- Growth factor antagonistic treatment of cancer with suramin (1990) (0)
- Reductase inhibitors employing 3-hydroxy-3-methylglutaryl coenzyme to as a modality for cancer therapy. (1993) (0)
- Reversal of methotrexate (mtx) high affinity binding in l1210 cells. Abstr. (1978) (0)
- Pharmacology of 13c / s-Retinoic Acid in Humans 1 (2006) (0)
- Molecular mechanisms of prostate cancer cell death upon inhibition of arachidonate 5-lipoxygenase: Involvement of FAS/APO1-mediated signals (1999) (0)
- Pharmacology of lntraperitoneal Chemotherapy (1983) (0)
- Chapter 55 – Antioxidants and Phytotherapy (2003) (0)
- Differentiating agents and nontoxic therapies : Hormone refractory prostate cancer (1999) (0)
- Administering Oral Liquid Drug Products: Handling Residual Drug Loss (1988) (0)
- General strategy of staging and therapy of non-Hodgkin's lymphomas. (1978) (0)
- Taxol inhibits protein isoprenylation in PC-3 prostate cancer cells (1995) (0)
- Successful Treatment of Advanced Metastatic Prostate Cancer following Chemotherapy Based on Molecular Profiling (2012) (0)
- Cyclic AMP induces transforming growth factor f82geneexpression andgrowth arrest inthehumanandrogen-independent prostate (1992) (0)
- Adriamycin cardiotoxicity — Assessment of late left ventricular dysfunction by radionuclide cineangiography (1980) (0)
- Studies of the Endocrine and Paracrine Effect of Tumor Produced Factors in Human Genitourinary Cancers (1991) (0)
- Myeloperoxidase is involved in Vincristine resistance in human myeloblastic leukemia (1994) (0)
- Personal Use of Prescription Drug Products from the Pharmacy Inventory (1988) (0)
- Mitochondrial Apoptosis: A New Foundation for Combining Agents in Prostate Cancer Treatment (2000) (0)
- Utilisation d'inhibiteurs de la 3-hydroxy-3-methylglutaryl coenzyme a-reductase comme methode de traitement du cancer (1993) (0)
- Taxane sensitivity markers in prostate cancer. (2016) (0)
- to MOPP Chemotherapy Bone Marrow Involvement in Hodgkin's Disease: Pathology and Response (2011) (0)
- Competitive BindingRadioassayfor 5-Fluorodeoxyuridine 5'-.Monophosphatein Tissues (2006) (0)
- Impact of Dutasteride on PSA Kinetics and Time to Progression in Men with PSA-only Recurrent Prostate Cancer (2021) (0)
- The use of inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase as a cancer treatment way (1993) (0)
- Administered Intraperitoneally to Patients with Ovarian Cancer Phase I and Pharmacological Studies of Adriamycin (2006) (0)
- Molecular characterization of advanced refractory prostate cancer. (2014) (0)
- A Phase I and Pharmacokinetic Study of Intravenous Phenylacetate in Patients with Cancer 1 (2006) (0)
- Intraperitoneal Adriamycin and 5-Fluorouracil in Ovarian Cancer (1984) (0)
- Phenylacetate inhibits protein prenylation in LNCaP cells transfected with the T24 H-ras gene (1995) (0)
- Biomarker patterns of localized and metastatic prostate cancer. (2015) (0)
- Establishment and Characterization of a Human Adrenocortical Carcinoma Cell Line That Expresses Multiple Pathways of Steroid Biosynthesis 1 (2006) (0)
This paper list is powered by the following services:
